Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
DRDermata Therapeutics, Inc. logo

Dermata Therapeutics, Inc. (DRMA)

NASDAQ Capital Market · Currency in USD
$0.78 ▼ -0.08 (-9.61%)
At close: Oct 23, 4:00 PM ET. Market closed.
$0.75 ▼ -0.03 (-3.67%)
After hours: Oct 23, 6:54 PM ET

Summary

Previous Close
$0.86
Open
$0.83
Day's Range
$0.77 – $0.84
52 Week Range
$0.60 – $4.66
Volume
119,319
Avg. Volume
530,132
Market Cap
$3.87M
Beta (5Y Monthly)
0.66
PE Ratio (TTM)
--
EPS (TTM)
-$2.08
Earnings Date
Nov 18, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$6.00

Profile: Dermata Therapeutics, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
9
CEO
Gerald T. Proehl

Dermata Therapeutics, Inc. engages in the development and distribution of over-the-counter pharmaceutical dermatology-focused products in the United States. The company develops direct-to-consumer skincare products, including foundation treatment products for skin renewal and clearing treatment products for the treatment of acne under the Tome brand. Dermata Therapeutics, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Earnings

Next report: Wed, Nov 18, 2026
EPS estimate -$0.55 · Revenue est. $25.00K
DateEst.Actual
Aug 11, 2026-$0.55-$0.74Miss
May 13, 2026-$0.53-$0.48Beat
Mar 26, 2026-$1.54-$1.52Beat
Nov 14, 2025-$1.59-$1.65Miss
Aug 13, 2025-$2.90-$1.66Beat
May 14, 2025-$4.50-$4.50Beat

Analyst view

Consensus price target
$6.00 ▲ +668.2%
Range $6.00 – $6.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on DRMA and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.